Submission for OMB Review; Social Services Block Grant (SSBG) Post-Expenditure Report (OMB #0970-0234)

 
CONTENT
74344
Federal Register / Vol. 85, No. 225 / Friday, November 20, 2020 / Notices
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington, DC 20551–0001, not later
than December 21, 2020.
A. Federal Reserve Bank of Cleveland
(Mary S. Johnson, Vice President), 1455
East Sixth Street, Cleveland, Ohio
44101–2566. Comments can also be sent
electronically to
Comments.applications@clev.frb.org:
1. Dollar Mutual Bancorp, Pittsburgh,
Pennsylvania; to acquire Standard AVB
Financial Corp. and its subsidiary bank,
Standard Bank, PaSB, both of
Murrysville, Pennsylvania.
Board of Governors of the Federal Reserve
System, November 17, 2020.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2020–25684 Filed 11–19–20; 8:45 am]
BILLING CODE 6210–01–P
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in the BHC Act
(12 U.S.C. 1842(c)).
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington DC 20551–0001, not later
than December 21, 2020.
A. Federal Reserve Bank of San
Francisco (Sebastian Astrada, Director,
Applications), 101 Market Street, San
Francisco, California 94105–1579:
1. DMG Bancshares, Inc., Irvine,
California; to become a bank holding
company by acquiring California First
National Bank, also of Irvine, California.
Board of Governors of the Federal Reserve
System, November 17, 2020.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2020–25680 Filed 11–19–20; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Submission for OMB Review; Social
Services Block Grant (SSBG) Post-
Expenditure Report (OMB #0970–0234)
AGENCY
: Office of Community Services,
Administration for Children and
Families, HHS.
ACTION
: Request for public comment.
SUMMARY
: The Administration for
Children and Families (ACF) is
requesting a 3-year extension of the
Social Services Block Grant (SSBG)
Post-Expenditure Report (OMB #0970–
0234, expiration 1/31/2021). Although
ACF initially proposed changes (see 85
FR 57863), after reconsideration during
the initial comment period, this request
is for an extension with no changes.
DATES
: Comments due within 30 days of
publication. OMB must make a decision
about the collection of information
between 30 and 60 days after
publication of this document in the
Federal Register. Therefore, a comment
is best assured of having its full effect
if OMB receives it within 30 days of
publication.
ADDRESSES
: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
SUPPLEMENTARY INFORMATION
:
Description: On an annual basis,
states and territories are required to
submit a Post-Expenditure Report that
details their use of SSBG funds in each
of the 29 service categories. Grantees are
required to submit their Post-
Expenditure Report within 6 months of
the end of the period covered by the
report.
OCS also allows states to use the Post-
Expenditure Reporting form to provide
pre-expenditure data for their annual
Intended Use Plans, which provides
estimates of the expenditures and
number of recipients by service
category.
Respondents: Agencies that
administer the SSBG at the state or
territory level, including the 50 States;
District of Columbia; Puerto Rico; and
the territories of American Samoa,
Guam, the Virgin Islands, and the
Commonwealth of Northern Mariana
Islands.
A
NNUAL
B
URDEN
E
STIMATES
Instrument Annual
number of
respondents
Annual
number of
responses per
respondent
Average
burden
hours per
response
Total/
annual
burden hours
Post-Expenditure Reporting Form ................................................................... 56 1 110 6,160
Post-Expenditure Reporting Form for Pre-Expenditure Data (funding esti-
mates for the Intended Use Plan) ................................................................ 56 1 2 112
VerDate Sep<11>2014 17:08 Nov 19, 2020 Jkt 253001 PO 00000 Frm 00035 Fmt 4703 Sfmt 4703 E:\FR\FM\20NON1.SGM 20NON1
khammond on DSKJM1Z7X2PROD with NOTICES
74345
Federal Register / Vol. 85, No. 225 / Friday, November 20, 2020 / Notices
Estimated Total Annual Burden
Hours: 6,272.
Authority: 42 U.S.C. 1397 through 1397e.
Mary B. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2020–25639 Filed 11–19–20; 8:45 am]
BILLING CODE 4184–24–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–D–0611]
Biosimilarity and Interchangeability:
Additional Draft Q&As on Biosimilar
Development and the Biologics Price
Competition and Innovation Act of
2009; Draft Guidance for Industry;
Availability
AGENCY
: Food and Drug Administration,
HHS.
ACTION
: Notice of availability.
SUMMARY
: The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a draft
guidance for industry entitled
‘‘Biosimilarity and Interchangeability:
Additional Draft Q&As on Biosimilar
Development and the BPCI Act.’’ The
question and answer (Q&A) format is
intended to inform prospective
applicants and facilitate the
development of proposed biosimilars
and proposed interchangeable
biosimilars, as well as to describe FDA’s
interpretation of certain statutory
requirements added by the Biologics
Price Competition and Innovation Act of
2009 (BPCI Act). This draft guidance
document provides new Q&As. It does
not replace the draft guidance document
entitled ‘‘New and Revised Draft Q&As
on Biosimilar Development and the
BPCI Act (Revision 2),’’ issued
December 12, 2018.
DATES
: Submit either electronic or
written comments on the draft guidance
by January 19, 2021 to ensure that the
Agency considers your comment on this
draft guidance before it begins work on
the final version of the guidance.
ADDRESSES
: You may submit comments
on any guidance at any time as follows:
Electronic Submissions
Submit electronic comments in the
following way:
Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2011–D–0611 for ‘‘Biosimilarity and
Interchangeability: Additional Draft
Q&As on Biosimilar Development and
the BPCI Act.’’ Received comments will
be placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-2015-
09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single
copies of this draft guidance to the
Division of Drug Information, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10001 New
Hampshire Ave., Hillandale Building,
4th Floor, Silver Spring, MD 20993–
0002, or the Office of Communication,
Outreach and Development, Center for
Biologics Evaluation and Research,
Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 71, Rm.
3128, Silver Spring, MD 20993–0002.
Send one self-addressed adhesive label
to assist that office in processing your
requests. See the
SUPPLEMENTARY
INFORMATION
section for electronic
access to the draft guidance document.
FOR FURTHER INFORMATION CONTACT
:
Sandra Benton, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, Rm. 1132,
Silver Spring, MD 20993, 301–796–
1042, sandra.benton@fda.hhs.gov, or
Stephen Ripley, Center for Biologics
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 7301,
Silver Spring, MD 20993–0002, 240–
402–7911, stephen.ripley@fda.hhs.gov.
SUPPLEMENTARY INFORMATION
:
I. Background
FDA is announcing the availability of
a draft guidance for industry entitled
‘‘Biosimilarity and Interchangeability:
VerDate Sep<11>2014 17:08 Nov 19, 2020 Jkt 253001 PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 E:\FR\FM\20NON1.SGM 20NON1
khammond on DSKJM1Z7X2PROD with NOTICES